Jason Thonhoff is a Neurology physician affiliated with Houston Methodist. OpenAlex indexes 50 publications with 2,123 citations (h-index 20); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6560 Fannin Street
Suite 802
Houston, TX 770302703
Telephone
713-441-3333Registry record last updated 12 Feb 2013.
Clinical trials
- Study in ALS With Abatacept & IL-2
Sponsor: The Methodist Hospital Research Institute
- T-regulatory Cells in ALS
Sponsor: The Methodist Hospital Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Biogen, Inc.Program year20248 payments
- Lilly USA, LLCProgram year20241 payment
- CATALYST PHARMACEUTICALS, INC.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
80.2%Other nervous system drugs30.6%Radicava Ors68%Skyclarys32%Part D<11 patientsGabapentinoids24.8%Gabapentin100%Part D<11 patients+ 1 more class in this area
Musculoskeletal
19.8%Survival of Motor Neuron 2 Splicing Modifier19.8%Evrysdi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2007–2010 per NIH RePORTER. The latest:
- Combined Stem Cell and Anti-Oxidative Therapy for ALS
University of Texas Med Br Galveston
FY2010$32,040F30NS060387 - Combined Stem Cell and Anti-Oxidative Therapy for ALS
University of Texas Med Br Galveston
FY2009$31,773F30NS060387 - Combined Stem Cell and Anti-Oxidative Therapy for ALS
University of Texas Med Br Galveston
FY2008$27,187F30NS060387
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Longitudinal Assessment of Biomarkers in <scp>ALS</scp> : Discriminative Biomarkers for Disease Progression and Survival
Annals of Clinical and Translational Neurology
2026 - Low-dose interleukin-2 in patients with mild to moderate Alzheimer’s disease: a randomized clinical trial
Alzheimer s Research & Therapy
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Bita Esmaeli, MD
Houston Methodist
Sherif Nagueh, MD
Houston Methodist
Neal Kleiman, MD
Houston Methodist
Miguel Quinones, MD
Houston Methodist
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”